Statins inhibit matrix metalloproteinase release from human lung fibroblasts

K. Kamio, X. D. Liu, H. Sugiura, S. Togo, S. Kawasaki, X. Wang, Y. Ahn, C. Hogaboam, S. I. Rennard

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


Pleiotropic effects of statins have been reported to include inhibition of matrix metalloproteinase (MMP) release from macrophages and endothelial cells. We evaluated whether statins would inhibit MMP release from human lung fibroblasts, which play a major role in remodelling processes. Monolayer and three-dimensional (3D) collagen gel cultures of fibroblasts were used. Cytokines (tumour necrosis factor-α and interleukin-1α) were used to induce MMP release and mRNA expression. Collagen degradation induced by cytokines and neutrophil elastase (NE) was evaluated by quantifying hydroxyproline. Atorvastatin inhibited MMP-1 and -3 release and mRNA expression in both culture systems. Similar results were obtained with simvastatin and fluvastatin. In 3D cultures where cytokines also stimulated MMP-9 release, atorvastatin also inhibited MMP-9 release. In 3D cultures, cytokines together with NE induced collagen degradation, which was also inhibited by atorvastatin. The effect of atorvastatin was reversed by mevalonate and geranylgeranyl-pyrophosphate but not by farnesyl-pyrophosphate. The current data suggest that statins may modulate remodelling processes mediated by fibroblasts by inhibiting MMP release.

Original languageEnglish (US)
Pages (from-to)637-646
Number of pages10
JournalEuropean Respiratory Journal
Issue number3
StatePublished - Mar 2010


  • Collagen
  • Degradation
  • Fibroblasts
  • Matrix metalloproteinases
  • Statins

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Statins inhibit matrix metalloproteinase release from human lung fibroblasts'. Together they form a unique fingerprint.

Cite this